Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tizaterkib (AZD-0364) is a potent and selective ERK2 inhibitor.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 22,000 | |||
2 mg | 在庫あり | ¥ 32,000 | |||
5 mg | 在庫あり | ¥ 53,000 | |||
10 mg | 在庫あり | ¥ 90,500 | |||
25 mg | 在庫あり | ¥ 151,000 | |||
50 mg | 在庫あり | ¥ 215,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 55,500 |
説明 | Tizaterkib (AZD-0364) is a potent and selective ERK2 inhibitor. |
ターゲット&IC50 | ERK2:0.6 nM |
In vitro | AZD-0364 is measured in the ERK2 mass spectrometry and A375 phospho-p90RSK assays (IC50s: 0.6 nM and 5.7 nM). AZD-0364 can inhibit the growth of a panel of cancer cell lines (A549, H2122, H2009, and Calu6 cell lines) with KRAS mutations as monotherapy. |
In vivo | In the A549 xenograft model, Selumetinib is dosed twice daily (BiD) 8 hours apart and AZD-0364 ethanesulfonic acid is dosed once daily (QD) 4 hours after the first Selumetinib dose. Both compounds are dosed continuously for 3 weeks. Both vehicles are dosed in the vehicle group. Both Selumetinib and AZD-0364 ethanesulfonic acid reduce tumor growth relative to vehicle-only control. The combination of Selumetinib and AZD-0364 ethanesulfonic acid results in a reduction in tumor growth. |
別名 | AZD-0364 |
分子量 | 494.5 |
分子式 | C24H24F2N8O2 |
CAS No. | 2097416-76-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (202.22 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tizaterkib 2097416-76-5 MAPK ERK inhibit AZD0364 Inhibitor Extracellular signal regulated kinases AZD-0364 AZD 0364 inhibitor